StreetInsider.com News Articles

Form DEFA14A Telomir Pharmaceuticals,

Wed, 19 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26947261.html

Form DEFA14A Telomir Pharmaceuticals,

Wed, 19 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26947261.html

Form SCHEDULE 13G/A Telomir Pharmaceuticals, Filed by: DEJORIA JOHN PAUL

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932182.html

Form SCHEDULE 13G/A Telomir Pharmaceuticals, Filed by: DEJORIA JOHN PAUL

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932182.html

Form 10-Q Telomir Pharmaceuticals, For: Jun 30

Thu, 13 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26922661.html

Form 10-Q Telomir Pharmaceuticals, For: Jun 30

Thu, 13 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26922661.html

Telomir publishes preclinical data on Telomir-Zn in cancer models

Mon, 10 Aug 2026 08:03:11 -0400

Telomir Pharmaceuticals (NASDAQ: TELO) announced the peer-reviewed publication of preclinical data showing its compound Telomir-Zn suppressed tumor growth in prostate cancer and triple-negative breast cancer (TNBC) models, according to a company statement.

The study, titled "Telomir-Zn Modulates Intracellular Iron and Copper to Inhibit JmjC Histone Demethylases and Suppress Tumor Growth in Prostate and Triple-Negative Breast Cancer," was published in the Journal of Oncology Research and Therapy, Volume 11, Issue 3.

The research found that Telomir-Zn targets histone demethylase enzymes, specifically the KDM2, KDM5, and KDM6 families, by depleting the intracellular iron they require for activity. In iron-rescue experiments, adding iron back to

Telomir publishes preclinical data on Telomir-Zn in cancer models

Mon, 10 Aug 2026 08:03:11 -0400

Form 8-K Telomir Pharmaceuticals, For: Aug 10

Mon, 10 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260810/26894708.html

Form 8-K Telomir Pharmaceuticals, For: Aug 10

Mon, 10 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260810/26894708.html

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Mon, 10 Aug 2026 08:00:00 -0400

Iron-Rescue Experiments Confirm Iron-Dependent Mechanism. Tumor Suppressor Gene Reactivation and Anti-Tumor and Anti-Metastatic Activity Across Multiple Models.

MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of preclinical data of Telomir-Zn suppressing tumor growth in prostate and triple-negative breast cancer (TNBC) models through selective modulation of intracellular iron and copper.

The manuscript, titled "Telomir-Zn Modulates Intracellular Iron and Copper to Inhibit JmjC Histone Demethylases and Suppress Tumor Growth in Prostate and Triple-Negative Breast Cancer," has been published

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Mon, 10 Aug 2026 08:00:00 -0400

Iron-Rescue Experiments Confirm Iron-Dependent Mechanism. Tumor Suppressor Gene Reactivation and Anti-Tumor and Anti-Metastatic Activity Across Multiple Models.

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Mon, 10 Aug 2026 08:00:00 -0400

Iron-Rescue Experiments Confirm Iron-Dependent Mechanism. Tumor Suppressor Gene Reactivation and Anti-Tumor and Anti-Metastatic Activity Across Multiple Models.

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Mon, 10 Aug 2026 08:00:00 -0400

Iron-Rescue Experiments Confirm Iron-Dependent Mechanism. Tumor Suppressor Gene Reactivation and Anti-Tumor and Anti-Metastatic Activity Across Multiple Models.

Form DEF 14A Telomir Pharmaceuticals, For: Jul 28

Tue, 28 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260728/26828179.html

Form DEF 14A Telomir Pharmaceuticals, For: Jul 28

Tue, 28 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260728/26828179.html

Form 4 Telomir Pharmaceuticals, For: Apr 16 Filed by: Del Giudice Matthew Paul